Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Rifampicin and Probenecid on Rongliflozin PK in Healthy Subjects
NCT05497674Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Feb 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rongliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Area Under the Curve and Peak Concentration. Started Feb 2022; status: completed.
02
Drugs
rongliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05497674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497674.